Herpes zoster in rheumatoid arthritis and in relation to biologic/targeted synthetic disease modifying anti-rheumatic drugs: a Swedish national study.

OBJECTIVE: To assess and compare the incidences of herpes zoster (HZ) in rheumatoid arthritis patients (RA) receiving biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), in b/tsDMARD-naïve RA, and general population. METHODS: We identified all patients with RA in Sweden 2014-2024, and b/tsDMARD starts among them, through register linkages. For each b/ts-DMARD treatment start, five age/sex-matched population controls were selected. A history of HZ was defined as a listing with an ICD-10 code for HZ and/or dispensation of an antiviral drug up to one year before treatment start. Incident HZ was defined as the first HZ ICD-10 code during follow-up accompanied by prescription of an antiviral within 90 days. RESULTS: 77694 unique RA patients contributed to the following: 69962 subjects in the b/tsDMARD-naïve cohort, and 20033 TNFi-, 9410 non-TNFi-, and 4023 JAKi-treatment episodes. Based on 95 incident HZ cases (incidence rate (IR) 2.0, 95% confidence interval 1.6-2.4 per1000 person-years) with TNFi, 55 cases (IR 2.4, 95% CI 1.8-3.1) with non-TNFi, 41 cases (IR 5.1, 95% CI 3.7-6.9) with JAKi, 561 cases (IR 1.5, 95% CI 1.4-1.6) in b/tsDMARD-naive RA and 494 cases (IR 0.6, 95% CI 0.6-0.7) in the general population, the multivariable-adjusted hazard ratio (using TNFi as reference) with JAKi was HR = 1.9; 95% CI 1.2-3.0 and HR = 0.9; 95% CI 0.6-1.3 for non-TNFi. CONCLUSION: The incidence of a first ever HZ is higher in b/tsDMARD-naïve patients compared to general population, is further and similarly increased in patients receiving TNFi or non-TNFi, and yet higher in those starting JAKi.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-11-13
DOI
https://doi.org/10.1093/rheumatology/keag642
Primary Topic
Rheumatoid Arthritis Research and Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Herpes zoster in rheumatoid arthritis and in relation to biologic/targeted synthetic disease modifying anti-rheumatic drugs: a Swedish national study.

Johan Karlsson Wallman, Daniela Di Giuseppe, Martin Björklund, Johan Askling et al.
1 links
PubMed
Rheumatoid Arthritis Research and Therapies
article

Herpes zoster in rheumatoid arthritis and in relation to biologic/targeted synthetic disease modifying anti-rheumatic drugs: a Swedish national study.

Johan Karlsson Wallman, Daniela Di Giuseppe, Martin Björklund, Johan Askling, Alf Kastbom, Jón Thorkell Einarsson, Meliha Crnkic Kapetanovic, Carl Turesson, Gerd-Marie Alenius, Anna Deminger, Helena Forsblad‐d’Elia, Lars Klareskog, Lotta Ljung, Bénédicte Delcoigne, Valgerður Sigurðardóttir, Aikaterini Chatzidionysiou
article en

Abstract

OBJECTIVE: To assess and compare the incidences of herpes zoster (HZ) in rheumatoid arthritis patients (RA) receiving biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), in b/tsDMARD-naïve RA, and general population. METHODS: We identified all patients with RA in Sweden 2014-2024, and b/tsDMARD starts among them, through register linkages. For each b/ts-DMARD treatment start, five age/sex-matched population controls were selected. A history of HZ was defined as a listing with an ICD-10 code for HZ and/or dispensation of an antiviral drug up to one year before treatment start. Incident HZ was defined as the first HZ ICD-10 code during follow-up accompanied by prescription of an antiviral within 90 days. RESULTS: 77694 unique RA patients contributed to the following: 69962 subjects in the b/tsDMARD-naïve cohort, and 20033 TNFi-, 9410 non-TNFi-, and 4023 JAKi-treatment episodes. Based on 95 incident HZ cases (incidence rate (IR) 2.0, 95% confidence interval 1.6-2.4 per1000 person-years) with TNFi, 55 cases (IR 2.4, 95% CI 1.8-3.1) with non-TNFi, 41 cases (IR 5.1, 95% CI 3.7-6.9) with JAKi, 561 cases (IR 1.5, 95% CI 1.4-1.6) in b/tsDMARD-naive RA and 494 cases (IR 0.6, 95% CI 0.6-0.7) in the general population, the multivariable-adjusted hazard ratio (using TNFi as reference) with JAKi was HR = 1.9; 95% CI 1.2-3.0 and HR = 0.9; 95% CI 0.6-1.3 for non-TNFi. CONCLUSION: The incidence of a first ever HZ is higher in b/tsDMARD-naïve patients compared to general population, is further and similarly increased in patients receiving TNFi or non-TNFi, and yet higher in those starting JAKi.

PubMed
Linköping University (SE), Uppsala University (SE), Lund University (SE), Karolinska Institutet (SE), Falun Hospital (SE), Center for Clinical Research Dalarna (SE), Stockholm Health Care Services (SE), Region Östergötland (SE), University of Gothenburg (SE), Umeå University (SE)
Good health and well-being
Rheumatoid Arthritis Research and Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon